Policy tailwinds & innovation breakthroughs drive HK pharma sector; multiple stocks hit YTD highs

1. Pharma Sector Surges, Hang Seng Healthcare Index Leads

On July 30, 2026, Hong Kong's market saw a collective surge in pharma stocks. The Hang Seng Healthcare Index expanded its afternoon gains to 4.2%, its largest single-day rise in three months. Among constituents, BeiGene (06160.HK) rose over 6%, Innovent Biologics (01801.HK) gained 5.8%, Akeso (09926.HK) jumped 7.2%, and GenScript Biotech (01548.HK) added 4.5%. CXO leader WuXi AppTec (02359.HK) climbed 3.9%, and WuXi Biologics (02269.HK) rose 4.1%.

2. Policy Tailwinds Accelerate Innovative Drug Access

On the news front, the National Healthcare Security Administration (NHSA) released the "Several Measures to Accelerate Medical Insurance Access for Innovative Drugs (Draft for Comments)" on the evening of July 29, proposing a fast-track channel for Class 1 new drugs: "submit upon acceptance, negotiate upon acceptance, list upon negotiation," shortening the time from approval to insurance coverage. Industry estimates suggest the average access cycle will shrink from the current 12–18 months to within 6 months under the new rules. This directly benefits innovative drug firms with strong pipelines, especially in hot areas like PD-1, ADC, and bispecific antibodies.

Meanwhile, data from the CDE of the NMPA shows that 15 domestic innovative drugs have received clinical approval since July, including Innovent's IBI-363 (PD-1/IL-2 bispecific) and Akeso's AK-132 (TIGIT monoclonal), both drawing market attention. BeiGene's tislelizumab also won approval this week for a new indication: first-line treatment of non-small cell lung cancer.

3. Fund Flows Improve, Southbound Investors Increase Holdings

On the fund flow side, southbound capital net bought over HK$3 billion in HK pharma stocks today, the highest in nearly two months. BeiGene, Innovent, and WuXi Biologics saw net inflows of HK$520 million, HK$480 million, and HK$360 million respectively. Institutions note that the pharma sector's valuation had fallen to historical lows due to factors like volume-based procurement and overseas geopolitical risks—the Hang Seng Healthcare Index's P/E (TTM) stands at just 21x, near the 15th percentile over the past five years. Policy catalysts coupled with the valuation trough are attracting capital back.

Notably, HK pharma ETFs also traded at a visible premium today, with the ChinaAMC Hang Seng Pharma ETF (03072.HK) showing a premium rate exceeding 3%, indicating strong chasing sentiment among on-exchange investors.

4. Technical and Sentiment Factors Converge, Short-Term Bullishness Grows

Technically, the Hang Seng Healthcare Index broke above its 60-day moving average on heavy volume today, with the MACD forming a golden cross and the RSI in the neutral-to-strong zone above 50, suggesting ample short-term momentum. In terms of sentiment, pharma trading volume rose to 18% of total Hong Kong market turnover today, the highest level this year, signaling significantly increased investor attention on pharma stocks.

5. Outlook: Focus on Innovative Drug Uptake and Reimbursement Negotiations

Looking ahead, analysts believe the pharma sector's rally sustainability hinges on two factors: first, the actual speed of innovative drug market uptake after implementation of the policy details; second, the 2026 national medical insurance reimbursement negotiations scheduled for September. The CITIC Securities pharma team noted that the policy's strength exceeded expectations and is expected to usher in a new upcycle for the innovative drug industry. However, after a large short-term rally, technical pullbacks may occur, so investors are advised to position in leading companies with core clinical data advantages at lower levels.

Additionally, attention should be paid to the impact of overseas liquidity changes on Hong Kong stocks overall. If the Fed's rate hike expectations intensify again, it could weigh on valuations of Hong Kong's growth sectors. However, overall, the pharma sector offers medium- to long-term allocation value given current cost-effectiveness and policy support.